US FDA approves Blue Earth Diagnostics’ Posluma (flotufolastat F 18) injection, first radiohybrid PSMA targeted PET imaging agent for prostate cancer

Blue Earth Diagnostics

30 May 2023 - Posluma will be commercially available in the United States in early June 2023.

Blue Earth Diagnostics today announced US FDA approval for its optimised, high-affinity radiohybrid prostate specific membrane antigen targeted PET imaging agent, Posluma (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3).

Read Blue Earth Diagnostics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , US , Diagnostic agent